Show simple item record

dc.contributor.authorSaif, Jaimy
dc.contributor.authorSchwarz, Theresa M.
dc.contributor.authorChau, David Y.S.
dc.contributor.authorHenstock, James
dc.contributor.authorSami, Paramjit
dc.contributor.authorLeicht, Simon F.
dc.contributor.authorHermann, Patrick C.
dc.contributor.authorAlcala, Sonia
dc.contributor.authorMulero, Francisca
dc.contributor.authorShakesheff, Kevin M.
dc.contributor.authorHeeschen, Christopher
dc.contributor.authorAicher, Alexandra
dc.date.accessioned2013-12-03T15:59:59Z
dc.date.available2013-12-03T15:59:59Z
dc.date.issued2010-10
dc.identifier.citationSaif , J , Schwarz , T M , Chau , D Y S , Henstock , J , Sami , P , Leicht , S F , Hermann , P C , Alcala , S , Mulero , F , Shakesheff , K M , Heeschen , C & Aicher , A 2010 , ' Combination of Injectable Multiple Growth Factor-Releasing Scaffolds and Cell Therapy as an Advanced Modality to Enhance Tissue Neovascularization ' , Arteriosclerosis, Thrombosis, and Vascular Biology , vol. 30 , no. 10 , pp. 1897-1904 . https://doi.org/10.1161/ATVBAHA.110.207928
dc.identifier.issn1079-5642
dc.identifier.urihttp://hdl.handle.net/2299/12256
dc.description.abstractObjective-Vasculogenic progenitor cell therapy for ischemic diseases bears great potential but still requires further optimization for justifying its clinical application. Here, we investigated the effects of in vivo tissue engineering by combining vasculogenic progenitors with injectable scaffolds releasing controlled amounts of proangiogenic growth factors. Methods and Results-We produced biodegradable, injectable polylactic coglycolic acid-based scaffolds releasing single factors or combinations of vascular endothelial growth factor, hepatocyte growth factor, and angiopoietin-1. Dual and triple combinations of scaffold-released growth factors were superior to single release. In murine hindlimb ischemia models, scaffolds releasing dual (vascular endothelial growth factor and hepatocyte growth factor) or triple combinations improved effects of cord blood-derived vasculogenic progenitors. Increased migration, homing, and incorporation of vasculogenic progenitors into the vasculature augmented capillary density, translating into improved blood perfusion. Most importantly, scaffold-released triple combinations including the vessel stabilizer angiopoietin-1 enhanced the number of perivascular smooth muscle actin(+) vascular smooth muscle cells, indicating more efficient vessel stabilization. Conclusion-Vasculogenic progenitor cell therapy is significantly enhanced by in vivo tissue engineering providing a proangiogenic and provasculogenic growth factor-enriched microenvironment. Therefore, combined use of scaffold-released growth factors and cell therapy improves neovascularization in ischemic diseases and may translate into more pronounced clinical effectsen
dc.format.extent8
dc.language.isoeng
dc.relation.ispartofArteriosclerosis, Thrombosis, and Vascular Biology
dc.subjectangiogenesis
dc.subjectischemia
dc.subjectprogenitor cells
dc.subjecttissue engineering
dc.subjectENDOTHELIAL PROGENITOR CELLS
dc.subjectMARROW MONONUCLEAR-CELLS
dc.subjectSTEM-CELLS
dc.subjectCORD BLOOD
dc.subjectPOSTNATAL NEOVASCULARIZATION
dc.subjectLIMB ISCHEMIA
dc.subjectIN-VIVO
dc.subjectANGIOPOIETIN-1
dc.subjectMODEL
dc.subjectANGIOGENESIS
dc.titleCombination of Injectable Multiple Growth Factor-Releasing Scaffolds and Cell Therapy as an Advanced Modality to Enhance Tissue Neovascularizationen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionDepartment of Pharmacy
dc.description.statusPeer reviewed
rioxxterms.versionofrecord10.1161/ATVBAHA.110.207928
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record